OptiNose

OptiNose P/B

Delisted

The P/B (Price-to-Book Ratio) of OptiNose (OPTN) as of Nov 11, 2026 is -2.41. In the previous year, P/B (Price-to-Book Ratio) was -1.12 — a change of 114.58% (lower).

P/B

-2.41

YoY

114.58%

Last updated:

P/B (Price-to-Book Ratio) of OptiNose is 2024 -2.41 . P/B (Price-to-Book Ratio) of OptiNose was 2023 -1.12 . It decreases by 114.58% lower compared to the previous year.

The OptiNose P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2017
0.63 USD
Jan 1, 2018
0.82 USD
Jan 1, 2019
1.58 USD
Jan 1, 2020
14.32 USD
Jan 1, 2021
-4.47 USD
Jan 1, 2022
-1.72 USD
Jan 1, 2023
-1.12 USD
Jan 1, 2024
-2.41 USD
The OptiNose P/B history
YEARP/BYoY
-2.41+114.58%
-1.12-34.62%
-1.72-61.55%
-4.47-131.18%
14.32+807.23%
1.58+92.60%
0.82+30.25%
0.63-102.48%
-25.33+607.32%
-3.58—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OptiNose Stock analysis

What does OptiNose do? OptiNose, Inc. develops and commercializes pharmaceutical products for ear, nose, and throat specialists and allergy specialists. The company's lead product, XHANCE (fluticasone propionate) nasal spray, uses a breath powered exhalation delivery system to treat chronic rhinosinusitis with nasal polyps. XHANCE is marketed as a topically acting anti-inflammatory corticosteroid that delivers medication directly to the site of inflammation. The company also has product candidates including XHANCE for chronic sinusitis, OPN-300, and OPN-021, which are part of its pipeline for ENT and allergy treatments. XHANCE is the company's primary revenue-generating product, targeting ENT and allergy specialists who prescribe it to patients with chronic rhinosinusitis and nasal polyps. The product's differentiated clinical profile positions it as a potential standard of care in its therapeutic area. Other pipeline products like OPN-300 and OPN-021 are in development but not yet commercialized, so they do not contribute to current revenue streams. The company's business model relies on the commercialization of XHANCE, which is sold to healthcare providers and patients through pharmaceutical distribution channels. ENT and allergy specialists are the key buyers of XHANCE, as it is designed specifically for their patient populations. The company's focus on nasal polyps and chronic sinusitis treatments aligns with the needs of these medical specialists. OptiNose is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OptiNose stock

P/B (Price-to-Book Ratio) of OptiNose is -2.41 in 2024.

P/B (Price-to-Book Ratio) of OptiNose changed from -1.12 to -2.41, representing a 114.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) OptiNose since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s OptiNose with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — OptiNose

All Key Metrics — OptiNose